Proposed Secondary Placing

Elixirr International plc (ELIX.L), an established, global award-winning, challenger consultancy, announces that it is undertaking a secondary placing of existing ordinary shares.

Following its recent results roadshow and indications of institutional demand, the Company is seeking to undertake a secondary placing to fulfil this demand through a bookbuilding process undertaken by the Company's broker. The demand will be satisfied by:

• Certain vendors of Hypothesis Group LLC, a business previously acquired by Elixirr, whose restrictions on sale of their Elixirr shares will be released by the Company. These individuals are unconnected with Elixirr and have not worked in either Hypothesis or Elixirr since acquisition
• Another shareholder who does not work in the business
• Certain current and former Partners of Elixirr (all non-PDMRs)

The secondary placing will total £12m of existing ordinary shares of 0.005 pence each ("Ordinary Shares") in the capital of the Company (the "Placing Shares") at a price of 750 pence per Placing Share (the "Placing").

The vendors of Hypothesis together with other non-Partner sellers are seeking to sell £8.4m in total with the balance being sold by Elixirr Partners (non-PDMRs).

Cavendish Capital Markets Limited ("Cavendish") is acting as sole bookrunner in relation to the Placing.

The sale of the Placing Shares will be effected by way of an accelerated bookbuild to institutional investors which will be launched immediately following this announcement (the "Bookbuild"). Cavendish will determine the amount of Placing Shares each of the Selling Shareholders will sell as part of the Placing.

A further announcement noting the number of Placing Shares sold will be made following completion of the Bookbuild.

The timing for the close of the Bookbuild and the distribution of allocations will be at the absolute discretion of Cavendish.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placing. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Cavendish will only procure investors who meet the criteria of professional clients and eligible counterparties.